227Th-trastuzumab (Bayer)

N/A

Report date: 2025/09/24 17:41:35

Base Information

Drug Name227Th-trastuzumab (Bayer)
Drug Alias Namethorium-227-trastuzumab (Algeta)thorium-227-trastuzumab (Bayer)227Th-trastuzumab (Algeta)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Monoclonal antibody conjugateBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody conjugate +[5] 
Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 antagonists
TargetsReceptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryNorway
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesAlgeta ASA
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAlgeta ASABayer AG
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A